Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study

Annals of Oncology

Volumn 15, Issue 12, 2004, Pages 1773-1781

  Pozzo, C ^a   Barone, Carlo ^a   Szanto, J ^b   Padi, E ^b   Peschel, C ^c   Bukki J ^c   Gorbunova, V ^d   Valvere, V ^e   Zaluski, J ^f   Biakhov, M ^g   Zuber, E ^h   Jacques, C ^h   Bugat, R ⁱ  

^a CATHOLIC UNIVERSITY   (Italy)

^b Szt Margarit Hospital   (Hungary)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d All Union CRC   (Russian Federation)

^e Estonian Oncology Center   (Estonia)

^f Hiekoskopie Centrum   (Poland)

^g Moscow City Oncology Clinical Hospital 62   (Russian Federation)

^h SANOFI   (France)

ⁱ INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

5 FU FA; Advanced gastric cancer; Cisplatin; Irinotecan; Phase II

Indexed keywords

ANTIDIARRHEAL AGENT; CISPLATIN; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; METOCLOPRAMIDE; ONDANSETRON; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CEREBELLUM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 19944424421     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh473     Document Type: Article

References (37)

1. Parkin DM, Whelan SL, Ferlay J et al. Cancer Incidence in Five Continents, Vol. VIII. Lyon: IARC 2002.
2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
3. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
4. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
5. Panzini I, Gianni L, Fattori PP et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88: 21-27.
6. Bajetta E, Buzzoni R, Mariani L et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13: 299-307.
7. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
8. Meyerhardt JA, Fuchs CS. Chemotherapy options for gastric cancer. Semin Radiat Oncol 2002; 12: 176-186.
9. Wils JA, Klein HO, Wagener DJ et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-831.
10. Kelsen D, Atiq OT, Saltz L et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541-548.
11. Waters JS, Norman A, Cunningham D et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80: 269-272.
12. Cocconi G, Carlini P, Gamboni A et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 2003; 14: 1258-1263.
13. Vanhoefer U, Wagner T, Lutz M et al. Randomized phase II study of weekly 24h infusion of high dose 5-FU±folinic acid (HD-FU±FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953. Eur J Cancer 2001; 37 (Suppl 6): (Abstr S27).
14. Hasham-Jiwa N, Kasakura Y, Ajani JA. Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001. Int J Clin Oncol 2002; 7: 219-224.
15. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
16. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
17. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
18. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
19. Futatsuki K, Wakui A, Nakao I et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994; 21: 1033-1038.
20. Hecht JR, Blanke CD, Benson AB 3rd, Lenz HJ. Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Oncology (Huntingt) 2003; 17 (Suppl 8): 13-15.
21. Köhne CH, Wils J, Lorenz M et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization for Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003; 21: 3721-3728.
22. Li-Shin L, Hecht J. A phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal (GE) junction. Proc Am Soc Clin Oncol 2000; 19: 289a (Abstr 1130).
23. Ajani JA, Baker J, Pisters PW et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 2002; 16 (Suppl 5): 16-18.
24. Boku N, Ohtsu A, Shimada Y et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-323.
25. Er O, Coskun HS, Solak Y, Altinbas M. Irinotecan plus cisplatin combination against metastatic gastric adenocarcinoma: preliminary results of phase II study. Proc Am Soc Clin Oncol 2002; 21: 124b (Abstr 2310).
26. Takiuchi H, Kurihara M, Koizumi W et al. Phase I/II study of CPT-11 plus CDDP in patients with advanced gastric carcinoma. Proc Am Soc Clin Oncol 2000; 19: 275a (Abstr 1074).
27. Assersohn L, Brown G, Cunningham D et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15: 64-69.
28. Blanke CD, Haller DG, Benson AB et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol 2001; 12: 1575-1580.
29. Findlay MPN, Ackland S, Gebski V et al. Phase II study of irinotecan, leucovorin and 5FU (ILF) in advanced gastric cancer. Proc Am Soc Clin Oncol 2001; 20: 165a (Abstr 655).
30. de Jonge MJ, Sparreboom A, Planting AS et al. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. J Clin Oncol 2000; 18: 187-194.
31. Ajani JA, Baker J, Pisters PW et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94: 641-646.
32. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
33. Köhne CH, Catane R, Klein B et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003; 89: 997-1001.
34. Bouché O, Raoul JL, Giovanini M et al. Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): Final results of study FFCD 9803. Proc Am Soc Clin Oncol 2003; 22: 258 (Abstr 1033).
35. Ajani JA, Fairweather J, Pisters PW, Charnsangavej C. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 2000; 14: 19-21.
36. Louvet C, Andre T, Tigaud JM et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-4548.
37. Mai M, Sakata Y, Kanamaru R et al. A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). Gan To Kagaku Ryoho 1999; 26: 487-496.